Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 4 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA889
—Terminated (no company submission)17 May 2023Current
Risankizumab for previously treated moderately to severely active Crohn's disease
NICE TA888
RisankizumabOptimised17 May 2023Current
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE TA887
OlaparibRecommended10 May 2023Current
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
NICE TA886
OlaparibRecommended10 May 2023Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA885
PembrolizumabRecommended (Cancer Drugs Fund)3 May 2023Replaced by TA939
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)
NICE TA884
CapmatinibTerminated (no company submission)3 May 2023Current
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA883
TafasitamabNot recommended3 May 2023Current
Voclosporin with mycophenolate mofetil for treating lupus nephritis
NICE TA882
VoclosporinRecommended3 May 2023Current
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
NICE TA881
RipretinibNot recommended3 May 2023Current
Tezepelumab for treating severe asthma
NICE TA880
TezepelumabOptimised20 Apr 2023Current
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal)
NICE TA879
Trastuzumab deruxtecanTerminated (no company submission)6 Apr 2023Current
Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19
NICE TA878
Nirmatrelvir, Sotrovimab, TocilizumabOptimised Recommended Not recommended29 Mar 2023
Updated 26 Feb 2026
Current
Finerenone for treating chronic kidney disease in type 2 diabetes
NICE TA877
FinerenoneOptimised23 Mar 2023Current
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
NICE TA876
NivolumabRecommended22 Mar 2023Current
Semaglutide for managing overweight and obesity
NICE TA875
SemaglutideOptimised8 Mar 2023
Updated 4 Sep 2023
Current
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
NICE TA874
Polatuzumab VedotinOptimised1 Mar 2023Current
Cannabidiol for treating seizures caused by tuberous sclerosis complex
NICE TA873
CannabidiolOptimised1 Mar 2023Current
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
NICE TA872
Axicabtagene CiloleucelRecommended28 Feb 2023Current
Eptinezumab for preventing migraine
NICE TA871
EptinezumabOptimised1 Mar 2023Current
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA870
IxazomibOptimised22 Feb 2023Current
Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal)
NICE TA869
TeclistamabTerminated (no company submission)16 Feb 2023Replaced by TA1015
Vutrisiran for treating hereditary transthyretin-related amyloidosis
NICE TA868
VutrisiranRecommended15 Feb 2023Current
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal)
NICE TA867
MitapivatTerminated (no company submission)16 Feb 2023Current
Regorafenib for previously treated metastatic colorectal cancer
NICE TA866
RegorafenibRecommended8 Feb 2023Current
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
NICE TA865
NivolumabOptimised8 Feb 2023Current
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
NICE TA864
NintedanibRecommended1 Feb 2023Current
Somatrogon for treating growth disturbance in children and young people aged 3 years and over
NICE TA863
SomatrogonRecommended1 Feb 2023Current
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
NICE TA862
Trastuzumab deruxtecanRecommended (Cancer Drugs Fund)1 Feb 2023Current
Upadacitinib for treating active non-radiographic axial spondyloarthritis
NICE TA861
UpadacitinibOptimised1 Feb 2023Current
Maribavir for treating refractory cytomegalovirus infection after transplant
NICE TA860
MaribavirRecommended18 Jan 2023Current
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)
NICE TA859
Angiotensin IITerminated (no company submission)16 Jan 2023Current
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
NICE TA858
Lenvatinib, PembrolizumabOptimised11 Jan 2023Current
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
NICE TA857
NivolumabRecommended11 Jan 2023Current
Upadacitinib for treating moderately to severely active ulcerative colitis
NICE TA856
UpadacitinibRecommended4 Jan 2023Current
Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
NICE TA855
MobocertinibRecommended4 Jan 2023Current
Esketamine nasal spray for treatment-resistant depression
NICE TA854
EsketamineNot recommended14 Dec 2022Current
Avatrombopag for treating primary chronic immune thrombocytopenia
NICE TA853
AvatrombopagRecommended15 Dec 2022Current
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments
NICE TA852
—Recommended14 Dec 2022Current
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer
NICE TA851
PembrolizumabRecommended14 Dec 2022Current
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
NICE TA850
AmivantamabNot recommended14 Dec 2022Current
Cabozantinib for previously treated advanced hepatocellular carcinoma
NICE TA849
CabozantinibOptimised14 Dec 2022Current
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)
NICE TA848
CemiplimabTerminated (no company submission)1 Dec 2022Current
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)
NICE TA847
MepolizumabTerminated (no company submission)29 Nov 2022Current
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)
NICE TA846
MepolizumabTerminated (no company submission)29 Nov 2022Current
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)
NICE TA845
MepolizumabTerminated (no company submission)29 Nov 2022Current
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)
NICE TA844
LuspaterceptTerminated (no company submission)24 Nov 2022Current
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)
NICE TA843
LuspaterceptTerminated (no company submission)24 Nov 2022Current
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)
NICE TA842
TisagenlecleucelTerminated (no company submission)22 Nov 2022Current
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
NICE TA841
CarfilzomibTerminated (no company submission)22 Nov 2022Current
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)
NICE TA840
RuxolitinibTerminated (no company submission)16 Nov 2022Current
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)
NICE TA839
RuxolitinibTerminated (no company submission)16 Nov 2022Replaced by TA1054
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)
NICE TA838
Potassium CitrateTerminated (no company submission)2 Nov 2022Current
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
NICE TA837
PembrolizumabRecommended26 Oct 2022Current
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA836
PalbociclibRecommended26 Oct 2022Current
Fostamatinib for treating refractory chronic immune thrombocytopenia
NICE TA835
FostamatinibOptimised19 Oct 2022Current
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)
NICE TA834
—Terminated (no company submission)12 Oct 2022Replaced by TA1045
Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA833
ZanubrutinibOptimised19 Oct 2022Current
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids
NICE TA832
Relugolix, EstradiolRecommended19 Oct 2022Current
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
NICE TA831
OlaparibNot recommended5 Oct 2022Replaced by TA887
Pembrolizumab for adjuvant treatment of renal cell carcinoma
NICE TA830
PembrolizumabRecommended19 Oct 2022Current
Upadacitinib for treating active ankylosing spondylitis
NICE TA829
UpadacitinibOptimised30 Sep 2022Current
Ozanimod for treating moderately to severely active ulcerative colitis
NICE TA828
OzanimodOptimised5 Oct 2022Current
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
NICE TA827
AzacitidineRecommended5 Oct 2022Current
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)
NICE TA826
VedolizumabTerminated (no company submission)21 Sep 2022Current
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis
NICE TA825
AvacopanRecommended21 Sep 2022Current
Dexamethasone intravitreal implant for treating diabetic macular oedema
NICE TA824
DexamethasoneOptimised14 Sep 2022Current
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA823
AtezolizumabRecommended (Cancer Drugs Fund)28 Sep 2022Replaced by TA1071
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)
NICE TA822
MelphalanTerminated (no company submission)14 Sep 2022Current
Avalglucosidase alfa for treating Pompe disease
NICE TA821
Avalglucosidase alfaRecommended24 Aug 2022Current
Brolucizumab for treating diabetic macular oedema
NICE TA820
—Optimised31 Aug 2022Current
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
NICE TA819
Sacituzumab GovitecanRecommended17 Aug 2022Current
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
NICE TA818
NivolumabOptimised17 Aug 2022Current
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
NICE TA817
NivolumabOptimised10 Aug 2022Current
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
NICE TA816
AlpelisibOptimised10 Aug 2022Current
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA815
GuselkumabOptimised10 Aug 2022Current
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
NICE TA814
Abrocitinib, Upadacitinib, TralokinumabOptimised3 Aug 2022Current
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
NICE TA813
AsciminibRecommended3 Aug 2022Current
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer
NICE TA812
PralsetinibNot recommended3 Aug 2022Current
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)
NICE TA811
DuvelisibTerminated (no company submission)27 Jul 2022Current
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
NICE TA810
AbemaciclibRecommended20 Jul 2022Current
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
NICE TA809
ImlifidaseOptimised20 Jul 2022Current
Fenfluramine for treating seizures associated with Dravet syndrome
NICE TA808
—Optimised8 Jul 2022Current
Roxadustat for treating symptomatic anaemia in chronic kidney disease
NICE TA807
RoxadustatOptimised13 Jul 2022Current
Belimumab for treating lupus nephritis (terminated appraisal)
NICE TA806
BelimumabTerminated (no company submission)13 Jul 2022Current
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
NICE TA805
Icosapent EthylOptimised13 Jul 2022Current
Teduglutide for treating short bowel syndrome
NICE TA804
TeduglutideRecommended30 Jun 2022Current
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA803
RisankizumabOptimised13 Jul 2022Current
Cemiplimab for treating advanced cutaneous squamous cell carcinoma
NICE TA802
CemiplimabOptimised29 Jun 2022Current
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
NICE TA801
PembrolizumabOptimised29 Jun 2022Current
Faricimab for treating wet age-related macular degeneration
NICE TA800
FaricimabOptimised29 Jun 2022Current
Faricimab for treating diabetic macular oedema
NICE TA799
FaricimabOptimised29 Jun 2022Current
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA798
DurvalumabOptimised22 Jun 2022Current
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)
NICE TA797
Enfortumab VedotinTerminated (no company submission)15 Jun 2022Current
Venetoclax for treating chronic lymphocytic leukaemia
NICE TA796
VenetoclaxRecommended15 Jun 2022Current
Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA795
IbrutinibNot recommended8 Jun 2022Current
Diroximel fumarate for treating relapsing–remitting multiple sclerosis
NICE TA794
Diroximel FumarateOptimised8 Jun 2022Current
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)
NICE TA793
AnifrolumabTerminated (no company submission)8 Jun 2022Current
Filgotinib for treating moderately to severely active ulcerative colitis
NICE TA792
FilgotinibRecommended1 Jun 2022Current
Romosozumab for treating severe osteoporosis
NICE TA791
RomosozumabOptimised25 May 2022Current
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)
NICE TA790
—Terminated (no company submission)25 May 2022Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.